We’ve put together a compilation of the 12 Healthcare Stocks with Insider Buying in 2025, highlighting Regencell Bioscience Holdings Limited as a standout.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) leads our selection for demonstrating notable insider buying. This biopharmaceutical firm, based in Hong Kong, is focused on developing Traditional Chinese Medicine (TCM) therapies for neurocognitive conditions such as ADHD and autism spectrum disorder (ASD).
A significant achievement occurred on September 21, 2025, when RGC was included in the S&P Global BMI Index, enhancing its recognition among institutional and passive investors. This inclusion could improve liquidity and help mitigate the volatility of the stock, which has experienced significant fluctuations. Nevertheless, the company still grapples with critical hurdles, including a lack of revenue, consistent losses, and uncertain routes for regulatory approval of its treatments.
Clinically, Regencell Bioscience Holdings Limited (NASDAQ:RGC) reported favorable outcomes from its second efficacy trial involving standardized TCM formulas targeting ADHD and ASD, demonstrating an average symptom improvement of 37% without any adverse side effects. Although these results are promising, the company has yet to announce any FDA-approved products, keeping these treatments in the investigational phase.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) experienced significant volatility in mid-2025, reaching an astonishing approximate 14,899% year-to-date increase by June, fueled by speculative trading, a stock split, and enthusiasm surrounding trial outcomes. After this peak, share prices underwent sharp intraday variations and a retracement, though technical indicators as of September hint at a possible upward trend, bolstered by positive momentum and movement above the 50-day moving average.
While we recognize the investment potential of RGC, we believe that certain AI stocks present better upside potential with reduced downside risk. If you are on the lookout for an incredibly undervalued AI stock that could greatly benefit from Trump-era tariffs and the trend towards onshoring, check out our complimentary report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
